TCRX
Tscan Therapeutics Inc

842
Mkt Cap
$52.89M
Volume
530,679.00
52W High
$2.57
52W Low
$0.8824
PE Ratio
-0.83
TCRX Fundamentals
Price
$0.932
Prev Close
$0.9343
Open
$0.95
50D MA
$1.04
Beta
1.20
Avg. Volume
523,297.55
EPS (Annual)
-$1.14
P/B
0.37
Rev/Employee
$14,515.46
$147.72
Loading...
Loading...
News
all
press releases
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of +6.25% and +94.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
More News
News Placeholder
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·5d ago
News Placeholder
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of +9.43% and -67.32%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of "Hold" from Analysts
Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been assigned an average rating of "Hold" from the seven research firms that are covering the firm, MarketBeat.com reports. One...
MarketBeat·22d ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Shares Up 1.8% - What's Next?
TScan Therapeutics (NASDAQ:TCRX) Shares Up 1.8% - Still a Buy...
MarketBeat·25d ago
News Placeholder
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Average Recommendation of "Hold" from Brokerages
Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) have been given an average recommendation of "Hold" by the seven analysts that are presently covering the company, Marketbeat.com...
MarketBeat·2mo ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Acquires $67,950.00 in Stock
TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) major shareholder Lynx1 Capital Management Lp bought 75,500 shares of the company's stock in a transaction dated Monday, December 22nd. The...
MarketBeat·2mo ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Buys 75,500 Shares
TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) major shareholder Lynx1 Capital Management Lp acquired 75,500 shares of TScan Therapeutics stock in a transaction that occurred on Monday...
MarketBeat·2mo ago
News Placeholder
TScan Therapeutics (NASDAQ:TCRX) Major Shareholder Lynx1 Capital Management Lp Acquires 80,069 Shares
TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) major shareholder Lynx1 Capital Management Lp purchased 80,069 shares of the company's stock in a transaction that occurred on Friday...
MarketBeat·2mo ago
News Placeholder
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines PR Newswire...
PR Newswire·2mo ago
<
1
2
...
>

Latest TCRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.